Our firm represented PhaseV, an AI-based clinical trials optimization startup, in its $50 million Series A funding round, co-led by Accel and Insight Partners with participation from Viola Ventures, EXOR, and LionBird.
This new latest investment brings PhaseV’s total funding to $65 million.
The startup is aiming to revolutionize the drug development market by integrating applying cutting-edge AI to enhance clinical trial process, helping identify to detect planning flaws and better interpret trial results ahead of regulatory approval.
The legal team at EBN advising PhaseV included Viva Gayer, Amit Horovitz from our Corporate and Commercial Department and Dr. Eran Lempert and Tal Alon from our Tax Department
Read the full article on The Marker and Calcalist
+97237770150 
